BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 stu ...

Her latest study examines how reprogramming the tumor microenvironment improves long-term immune memory by targeting the IL6ra-Bcl6 axis in CD4 T cells, offering new hope for more effective GBM ...

One is using ARV-393, a PROTAC for blood cancers that degrades BCL6, a previously undruggable target. The second involves ARV-102, which degrades a protein relevant to neuroscience. “Our ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

The researchers engineered a unique molecular compound that binds together two proteins – BCL6 and CDK9 – to trigger the activation of apoptosis genes in cancer cells. By redirecting an ...

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein ...

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...

- Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 ...

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 ...